Novartis pulls bid to expand Pluvicto label for prostate cancer in EU
Source: SeekingAlpha
2026-04-24 11:26:33 ET
More on Novartis
- Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade)
- Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree
- Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth
- Sanofi, Arrowhead, Novartis among winners of EU recommendations this week
- WHO prequalifies Novartis’ Coartem Baby for infants
Read the full article on Seeking Alpha
For further details see:
Novartis pulls bid to expand Pluvicto label for prostate cancer in EU
Novartis AG
NASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
